ALT In our single-centre study of patients with cirrhosis hospitalized in ICU, we found that cirrhosis related to metabolic dysfunction-associated steatotic liver disease (MASLD) or metALD accounted for more than 1/3 of the cause of liver disease. The prognosis of MASLD patients was similar to that of ALD or metALD patients, although further development of HE was significantly more frequent in MASLD patients.

ALT The diagnostic and predictive capability of a number of faecal biomarkers were analysed using a study design including a cohort of new-onset treatment-naive IBD patients and symptomatic controls. The neutrophil proteins myeloperoxidase (MPO) and calprotectin (FC) displayed comparable diagnostic capacities as single markers. Combining FC and MPO resulted in improved diagnostics, indicating that MPO alone or combined with FC may add to the diagnostic power of faecal biomarkers. High values of neutrophil markers FC, MPO and human neutrophil lipocalin (HNL) at diagnosis were predictive of an aggressive disease course in patients with UC, information that can be of value when stratifying new-onset IBD patients.

ALT Out of 123 cirrhotic patients with cognitive complaints, 34% did not display covert HE but another cause of neurocognitive impairment (NI). Patients with covert HE has a higher probability of developing overt HE than patients with other causes of NI.